Table 3 Demographic and clinical parameters according to tertiles of circulating DPP4 activity in diabetic patients
Parameters | DPP4 (pmol/min/mL) | p value | ||
|---|---|---|---|---|
<5060 | 5060-6208 | >6208 | ||
Age (years) | 65 ± 9.1 | 66.2 ± 7.1 | 64.7 ± 9.7 | 0.836 |
Male/female (%) | 59/41 | 68/32 | 61/39 | 0.657 |
BMI (Kg/m2) | 32 ± 6.4 | 28.5 ± 4.5 | 29.4 ± 4.5 | 0.086 |
SBP (mmHg) | 140 ± 17 | 136 ± 23.8 | 141 ± 23.9 | 0.767 |
DBP (mmHg) | 80 (70-80) | 70 (60-80) | 75 (70-80) | 0.300 |
MBP (mm Hg) | 97.8 ± 8 | 93.6 ± 13.8 | 97.8 ± 13.4 | 0.395 |
PP (mmHg) | 63.3 ± 17.5 | 64.1 ± 18.4 | 64.3 ± 23.2 | 0.984 |
HbA1c (%) | 6.5 (6.1-7.4) | 6.5 (5.9-7.2) | 6.9 (6-7.9) | 0.555 |
Fasting glucose (mg/dL) | 112 (100-129) | 113 (106-169) | 117 (109-171) | 0.265 |
Comorbidities, (n, %) | ||||
Hypertension | 22, 82 | 22, 79 | 24, 85 | 0.997 |
Hypertriglyceridemia | 5, 19 | 6, 21 | 7, 25 | 0.811 |
Hypercholesterolemia | 4, 15 | 9, 32 | 10, 36 | 0.440 |
Obesity | 16, 60 | 9, 32 | 14, 50 | 0.230 |
CKD | 6, 22 | 5, 17 | 4, 14 | 0.409 |
Treatment (n, %) | ||||
Antidiabetic agents | ||||
Metformin | 9, 33 | 4, 14 | 12, 43 | 0.064 |
Sulfonylureas | 7, 26 | 7, 26 | 4, 14 | 0.199 |
Other oral anti-diabetic drugs | 5, 19 | 7, 26 | 10, 36 | 0.418 |
Insulin | 6, 22 | 7, 25 | 10, 36 | 0.664 |
Anti-hypertensive agents | ||||
ACEi/ARAs | 17, 63 | 15, 53 | 17, 61 | 0.634 |
Diuretics | 6, 22 | 7, 25 | 7, 25 | 0.938 |
Ca2 + -antagonists | 3, 11 | 9, 32 | 7, 25 | 0.104 |
Beta-blockers | 7, 26 | 7, 25 | 6, 21 | 0.888 |
Other pharmacological agents | ||||
Statins | 15, 55 | 18, 64 | 15, 57 | 0.824 |
Anti-coagulants | 5, 19 | 4, 14 | 5, 19 | 0.910 |
Anti-aggregants | 15, 56 | 15, 53 | 14, 50 | 0.902 |